Company Overview and News

China stocks plunge to two-year low on tariff threat; yuan sinks

2018-06-19 malaymail
NEW YORK, June 19 — China’s benchmark equity gauge tumbled to a two-year low and the yuan weakened as a worsening trade dispute with the US spurred panic selling. Bonds gained.
AAPL 1375

Shanghai, Hong Kong stocks plunge on trade war fears

2018-06-19 yahoo
Shanghai (AFP) - Shanghai and Hong Kong stocks plunge on Tuesday on investors' fears that the US and China could be heading for a full-blown trade war following tit-for-tat tariff threats.

2 Catalysts Emerging For Alibaba And JD.Com

2018-05-28 seekingalpha
An upcoming shopping festival would drum up media attention on e-commerce companies like Alibaba and The positive coverage on likely record-breaking sales could provide a short-term share price boost.

Down US$1t, Chinese stocks approach a pivotal level

2018-04-19 themalaymailonline
Investors look at an electronic board showing stock information at a brokerage house in Shanghai February 9, 2018. — Reuters picSHANGHAI, April 19 — In a Chinese stock market infatuated with round numbers, 3,000 has emerged as the latest fixation for investors trying to gauge the government’s commitment to ending a nearly US$1 trillion (RM3.89 trillion) selloff.

Tokyo leads Asian stocks lower in light holiday trade - Channel NewsAsia

2018-04-02 channelnewsasia
HONG KONG: Tokyo stocks drifted lower on Monday (Apr 2) in thin holiday trade, pulling down markets in China and South Korea, with the majority closed for the Easter holiday.
BHI 1375

Flash - China pork and farm shares jump on trade threats - France 24

2018-03-23 france24
Chinese pork and agriculture shares escaped the market downdraft from US-China trade tensions on Friday, rising sharply on anticipation that potential new barriers on American imports could fatten up the sales of domestic producers.

China pork and farm shares jump on trade threats - Channel NewsAsia

2018-03-23 channelnewsasia
SHANGHAI: Chinese pork and agriculture shares escaped the market downdraft from US-China trade tensions on Friday (Mar 23), rising sharply on anticipation that potential new barriers on American imports could fatten up the sales of domestic producers.

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...